share_log

4: Statement of changes in beneficial ownership of securities-Officer Dogan Meeshanthini

4: Statement of changes in beneficial ownership of securities-Officer Dogan Meeshanthini

4:持股變動聲明-高管 Dogan Meeshanthini
美股SEC公告 ·  2024/09/09 11:05

Moomoo AI 已提取核心訊息

Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,683,867 shares. The transaction, which took place in the open market, reflects the CEO's direct investment in the company's equity.
Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,683,867 shares. The transaction, which took place in the open market, reflects the CEO's direct investment in the company's equity.
Cardio Diagnostics Holdings, Inc.首席執行官Dogan Meeshanthini於2024年9月6日完成了公司股票的購買。此次交易涉及購買68,965股普通股,每股價格爲0.29美元。在此次交易後,Meeshanthini在公司的直接持股增加到總共1,683,867股。這次交易在公開市場上進行,反映了首席執行官對公司股權的直接投資。
Cardio Diagnostics Holdings, Inc.首席執行官Dogan Meeshanthini於2024年9月6日完成了公司股票的購買。此次交易涉及購買68,965股普通股,每股價格爲0.29美元。在此次交易後,Meeshanthini在公司的直接持股增加到總共1,683,867股。這次交易在公開市場上進行,反映了首席執行官對公司股權的直接投資。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息